Abstract
Anticoagulation to prevent left ventricular (LV) thrombus is recommended following anterior infarcts with extensive wall motion abnormalities (Class IIb, LOE C). Rapid reperfusion in contemporary ST-elevation myocardial infarction (STEMI) networks has reduced the incidence of LV thrombus. Additionally, current utilization of potent antithrombotic agents coupled with enhanced understanding of the risk of major bleeding with ‘triple therapy’ requires a reassessment of ‘prophylactic anticoagulation’. Utilizing a regional STEMI reperfusion inclusive registry, we sought to evaluate the outcomes of ‘prophylactic warfarin’ in patients discharged alive following an anterior STEMI with LV dysfunction (LVEF ≤40%).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
